DOI: https://doi.org/10.22141/2306-2436.9.2.2020.205211

Why do people with diabetes have poor results in the treatment of COVID-19? (review and practical recommenda-tions)

B.M. Mankovsky, O.A. Halushko

Abstract


Background. On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic. As of May 15, 2020, a total of 4,539,401 cases of COVID-19 and 303,551 deaths had been reported worldwide. In Ukraine, coronavirus infection COVID-19 was first diagnosed on March 3, 2020 in Chernivtsi, and on March 13 the first fatal case due to coronavirus infection was recorded. As of May 15, 2020, there were 17,330 cases of the disease in Ukraine, of which 476 were fatal (mortality - 2.7 %), 4473 patients recovered (25.8 % of those who fell ill). In Ukraine, as well as in the world as a whole, during the spread of severe acute respiratory syndrome coronavirus-2, data are constantly published that certain groups of patients are at higher risk of COVID-19. These include patients with hypertension, heart disease and diabetes mellitus (DM). The purpose was to analyze the causes of the negative impact of diabetes on the course of COVID-19 and to formulate recommendations for prevention and treatment for patients with DM and their doctors. Material and methods. To solve this problem, a search was carried out for publications using the search engines PubMed and Google Scholar. Search terms were used: COVID-19, diabetes mellitus, hyperglycemia, hypoglycemia, complications. As a result of the search for the indicated terms, a total of 267 publications were identified, published from the beginning of the epidemic in December 2019 to May 14, 2020. Results. The main risk factors for the development and severe course of ­COVID-19 are considered to be old age, arterial hypertension, diabetes mellitus (DM), cardiovascular and cerebrovascular diseases. Based on the analysis of specialized publications in the search engines PubMed and Google Scholar, the reasons for the negative impact of DM on the course and results of patients with COVID-19 treatment are established, recommendations are made for the prevention and treatment of patients in the case of a combination of COVID-19 disease and concomitant diabetes. Conclusions. We consider it appropriate to formulate recommendations for the management of patients with DM in the context of the COVID 19 pandemic created on the basis of the analysis of publications and modern international guidelines.

Keywords


COVID-19; diabetes mellitus; complications; prevention; treatment

References


World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. 11 March 2020. Geneva, Switzerland: World Health Organization; 2020. – [web-сторінка Internet]. Доступно: URL https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020.

Коронавірус в Україні. – [web-сторінка Internet]. Доступно: URL https://index.minfin.com.ua/ua/reference/coronavirus/ukraine/

Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. // Aging (Albany NY). – 2020. Apr 8;12. – doi: 10.18632/aging.103000.

Kosinski C., Zanchi A., Wojtusciszyn A. Diabetes and COVID-19 infection. // Rev Med Suisse. – 2020. May 6;16(692):939-943.

Hu L., Chen S., Fu Y., et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. // Clin Infect Dis. – 2020. May 3. pii: ciaa539. –doi: 10.1093/cid/ciaa539.

Huang R., Zhu L., Xue L., et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. // PLoS Negl Trop Dis. – 2020. May 8;14(5):e0008280. – doi: 10.1371/journal.pntd.0008280.

Itelman E., Wasserstrum Y., Segev A., et al. Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center. // Isr Med Assoc J. – 2020 May; 22(5):271-274. – PubMed PMID: 32378815.

Fadini G. P., Morieri M. L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. // J Endocrinol Invest. – 2020. Mar 28. – doi: 10.1007/s40618-020-01236-2.

CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. // MMWR Morb Mortal Wkly Rep. – 2020 Apr 3; 69(13):382-386. –doi: 10.15585/mmwr.mm6913e2.

Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. // N Engl J Med. – 2020. Mar 30. –doi: 10.1056/NEJMoa2004500.

Wu J., Li W., Shi X., et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). // J Intern Med. – 2020. Mar 27. –.doi: 10.1111/joim.13063.

Wang D., Hu B., Hu C., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. // JAMA. – 2020. Feb 7. – doi: 10.1001/jama.2020.1585.

Rosenberg E. S., Dufort E. M., Udo T., et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. // JAMA. – 2020. May 11. – doi: 10.1001/jama.2020.8630.

Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. // Lancet. – 2020. Mar 28; 395(10229):1054-1062. – doi: 10.1016/S0140-6736(20)30566-3.

Korean Society of Infectious Diseases and Korea Centers for Disease Control and Prevention. Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020. // J Korean Med Sci. – 2020. Mar 30; 35(12):e132. – doi: 10.3346/jkms.2020.35.e132.

Wu C., Chen X., Cai Y., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. // JAMA Intern Med. – 2020. Mar 13. – doi: 10.1001/jamainternmed.2020.0994.

Центр громадського здоров’я МОЗ України. Оперативна інформація. – [web-сторінка Internet]. Доступно: URL https://phc.org.ua/kontrol-zakhvoryuvan/inshi-infekciyni-zakhvoryuvannya/koronavirusna-infekciya-covid-19.

Deng S. Q., Peng H. J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. // J Clin Med. – 2020. Feb 20;9(2). pii:E575. – doi: 10.3390/jcm9020575.

Zhang J. J., Dong X., Cao Y. Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. // Allergy. – 2020. Feb 19. – doi: 10.1111/all.14238.

IDF Diabetes Atlas. 9th Edition 2019. – [web-сторінка Internet]. Доступно: URL https://www.diabetesatlas.org/en/

Maddaloni E., Buzzetti R.. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. // Diabetes Metab Res Rev. – 2020. Mar 31:e33213321. – doi: 10.1002/dmrr.3321.

Fu R., Li S. D., Song C. X., et al. Clinical significance of diabetes on symptom and patient delay among patients with acute myocardial infarction-an analysis from China Acute Myocardial Infarction (CAMI) registry. // J Geriatr Cardiol. – 2019. May; 16(5):395-400. – doi: 10.11909/j.issn.1671-5411.2019.05.002.

Yang J. K., Lin S. S., Ji X. J., Guo L. M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. // Acta Diabetol. – 2010;.47:193–9. – doi: 10.1007/s00592-009-0109-4.

Kleine-Weber H., Schroeder S., Krüger N., et al. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. // Emerg Microbes Infect. – 2020. Jan 21; 9(1):155-168. – doi: 10.1080/22221751.2020.1713705.

Raj V. S., Mou H., Smits S. L., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. // Nature. – 2013. Mar 14; 495(7440):251-4. – doi: 10.1038/nature12005.

Ilias I., Zabuliene L. Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms. // Med Hypotheses. – 2020 Mar 26; 139:109699. – doi: 10.1016/j.mehy.2020.109699.

Guo W., Li M., Dong Y., et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. // Diabetes Metab Res Rev. – 2020. Mar 31:e3319. – doi:10.1002/dmrr.3319.

Gheblawi M., Wang K., Viveiros A., et al. Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. // Circ Res. – 2020. Apr 8. – doi: 10.1161/CIRCRESAHA.120.317015.

Shahid Z., Kalayanamitra R., McClafferty B., et al. COVID-19 And Older Adults: What We Know. // J Am Geriatr Soc. – 2020 Apr 7. – doi: 10.1111/jgs.16472.

Cheng H., Wang Y., Wang G. Q. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. // J Med Virol. – 2020 Mar 27. – doi: 10.1002/jmv.25785.

Soro-Paavonen A., Gordin D., Forsblom C., et al.; FinnDiane Study Group. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. // J Hypertens. – 2012 Feb; 30(2):375-83. – doi: 10.1097/HJH.0b013e32834f04b6.

Gilbert A., Liu J., Cheng G., et al. A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy. // Biochem Med (Zagreb). – 2019 Feb 15; 29(1):010501. – doi: 10.11613/BM.2019.010501.

Stein R. COVID-19: Risk Groups, Mechanistic Insights, and Challenges. // Int J Clin Pract. – 2020. Apr 7:e13512. – doi: 10.1111/ijcp.13512.

Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for ­COVID-19 infection? // Lancet Respir Med. – 2020. Apr; 8(4):e21. – doi: 10.1016/S2213-2600(20)30116-8.

Danser A. H. J., Epstein M., Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. // Hypertension. – 2020. Mar 25: HYPERTENSIONAHA12015082. – doi: 10.1161/HYPERTENSIONAHA.120.15082.

EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic. – [web-сторінка Internet]. Доступно: URL https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic

Day M. Covid-19: Ibuprofen should not be used for managing symptoms, say doctors and scientists. // BMJ. – 2020. Mar 17; 368:m1086. – doi.org/10.1136/bmj.m1086.

Voiriot G., Philippot Q., Elabbadi A., et al. Risks related to the use of non-steroidal anti-inflammatory drugs in community acquired pneumonia in adult and pediatric patients. // J Clin Med. – 2019; 8(6): E786. – doi.org/10.3390/jcm8060786. pii.

The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. – [web-сторінка Internet]. Доступно: URL https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19

Застосування ліків при COVID-19. Спецпроект Державного експертного центру МОЗ. – [web-сторінка Internet]. Доступно: URL http://covid19.dec.gov.ua

Liu J., Cao R., Xu M., et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. // Cell Discov. – 2020. Mar 18; 6:16. – doi: 10.1038/s41421-020-0156-0.

Mercuro N. J., Yen C. F., Shim D. J., et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). // JAMA Cardiol. – 202.0 May 1. – doi: 10.1001/jamacardio.2020.1834.

Baretić M. Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic? // Diabetes Metab Syndr. – 2020. Apr 13; 14(4):355-356. – doi: 10.1016/j.dsx.2020.04.014.

Singh A. K., Singh A., Shaikh A., et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. // Diabetes Metab Syndr. – 2020. Mar 26;14(3):241-246. – doi: 10.1016/j.dsx.2020.03.011.

Gautret P., Lagier J. C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. // Int J Antimicrob Agents. – 2020. Mar 20:105949. – doi: 10.1016/j.ijantimicag.2020.105949.

Gupta R., Ghosh A., Singh A. K., Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. // Diabetes Metab Syndr. – 2020. Mar 10; 14(3):211-212. –doi: 10.1016/j.dsx.2020.03.002.

Puig-Domingo M., Marazuela M., Giustina A. ­COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. // Endocrine. – 2020. Apr 11. – doi: 10.1007/s12020-020-02294-5.

Pal R., Bhadada S. K. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? // Diabetes Res Clin Pract. – 2020. Apr 10:108146. – doi: 10.1016/j.diabres.2020.108146.

American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020. // Diabetes Care. – 2020. Jan; 43(Suppl 1):S193-S202. – doi: 10.2337/dc20-S015.

Mechanick J. I., Pessah-Pollack R., Camacho P., et al. American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for standardized production of clinical practice guidelines, algorithms, and checklists – 2017 Update. // Endocr Pract. – 2017. Aug; 23(8):1006-1021. – doi: 10.4158/EP171866.GL.

Flanagan D., Dhatariya K., Kilvert A.; Joint British Diabetes Societies (JBDS) for Inpatient Care group and Guidelines writing group. Self-management of diabetes in hospital: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. // Diabet Med. – 2018. Aug; 35(8):992-996. – doi: 10.1111/dme.13677.

Karslioglu French E., Donihi A. C., Korytkowski M.T. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. // BMJ. – 2019. May 29; 365:l1114. – doi: 10.1136/bmj.l1114.




Copyright (c) 2020 Health of Society

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020